Trials / Unknown
UnknownNCT03527888
Study of Anlotinib in Patients With Primary Malignant Bone Tumors
A Single-Arm, Open-Label, Multicenter Clinical Trial With Anlotinib Hydrochloride Capsule for Primary Malignant Bone Tumors With Recurrence and Distant Metastases
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 14 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of patients with recurrent and metastatic bone tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent |
Timeline
- Start date
- 2018-01-31
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2018-05-17
- Last updated
- 2019-05-21
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03527888. Inclusion in this directory is not an endorsement.